Celcuity Inc. Announces Pricing of Upsized Public Offering of 0.250% Convertible Senior Notes Due 2032

Celcuity Inc., a clinical-stage biotechnology company, announced the pricing of an upsized $500 million convertible senior notes offering due 2032, increased from the previously announced $400 million. The company plans to use net proceeds of approximately $484.3 million to repay Oxford Finance debt and fund working capital, clinical trials, and R&D. The convertible notes carry a 0.250% interest rate with a conversion price of approximately $124.53 per share, representing a 40% premium to the stock price on June 3, 2026.